Companies that face non-public government investigations frequently confront challenging questions regarding whether and when to disclose the existence of the investigation, how much to disclose, and any duty to update the disclosure as the investigation proceeds. The SEC recently filed a settled complaint alleging that Mylan committed accounting and disclosure violations for failing to timely disclose an otherwise confidential DOJ investigation into whether Mylan overcharged Medicaid for its largest revenue and profit generating product, the EpiPen. The investigation resulted in Mylan agreeing to pay $465 million to settle the investigation. The settlement papers are important reading for all public companies considering disclosure of government investigations.
Please click here to read the full alert memorandum.